目的: 研究糖尿病肾病(DKD)患者与健康对照人群血清色氨酸不同代谢通路中代谢物的差异,分析差异代谢物与临床指标之间的相关性。方法: 以包头医学院第一附属医院肾内科和内分泌科住院部患者为研究对象,选取10例DKD患者为疾病研究组,10例健康体检者为正常对照组,收集血液标本。采用靶向代谢组学方法分析两组人群中血清色氨酸及其代谢物的差异,进行生物信息学和统计学分析,阐明其在DKD中的意义。结果: 在两组血清中鉴定出5个差异代谢物,其中DKD患者血清中L-色氨酸(L-TRP)、5-羟色胺(5-HT)的水平明显低于健康对照组(P＜0.05),而5-羟基吲哚乙酸(5-HIAA)、犬尿氨酸(KYN)和3-吲哚丙酸(IPA)的水平则增加,差异具有统计学意义(P＜0.05),5-HIAA和IPA均与血肌酐呈显著正相关,与肾小球滤过率呈显著负相关。结论: DKD患者血清色氨酸代谢物水平与健康对照组相比具有明显的差异,其中的某些差异代谢物还与DKD的发生发展具有明显的相关性。
Objective: To study the differences of metabolites in different metabolic pathways of serum tryptophan in patients with diabetic kidney disease (DKD) and healthy controls, and analyze the correlation between differential metabolites and clinical indicators. Method: Taking patients in the Nephrology Department and Endocrinology Department of the First Affiliated Hospital of Baotou Medical College as the research objects, 10 DKD patients were selected as the disease study group, and 10 healthy subjects were selected as the normal control group, and blood samples were collected. The differences of serum tryptophan and its metabolites in the two groups were analyzed by targeted metabolomics method, and then biological information analysis and statistical analysis were performed to clarify its significance in DKD. Results: Five differential metabolites were identified in the serum of DKD patients and healthy controls. The levels of L-tryptophan (L-TRP) and serotonin (5-HT) in serum of DKD patients were significantly lower than those of healthy controls,the difference was statistically significant (P＜0.05).While the levels of 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), and 3-indolepropionic acid (IPA) are increased, the difference was also statistically significant(P＜0.05). There was a significant positive correlation between 5-HIAA and IPA with serum creatinine, and a significant negative correlation with glomerular filtration rate. Conclusions: Serum tryptophan metabolite levels in DKD patients were significantly different from those in healthy controls, and some of the differential metabolites are also significantly correlated with the occurrence and development of DKD.
[1] Hasegawa S, Inagi R. Harnessing metabolomics to describe the pathophysiology underlying progression in diabetic kidney disease[J]. Curr Diab Rep, 2021,21(7):21.
[2] Liu Y, Chen XF, Liu Y, et al. Metabolomic study of the protective effect of Gandi capsule for diabetic nephropathy[J]. Chem Biol Interact, 2019,314:108815.
[3] Chou CA, Lin CN, Chiu DTY, et al. Tryptophan as a surrogate prognostic marker for diabetic nephropathy[J]. J Diabetes Investig, 2018,9(2):366-374.
[4] Debnath S, Velagapudi C, Redus L, et al. Tryptophan metabolism in patients with chronic kidney disease secondary to type 2 diabetes: relationship to inflammatory markers[J].Int J Tryptophan Res, 2017,10:517489800.
[5] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 国际内分泌代谢杂志,2021,41(4):388-410.
[6] Brown KL, Darris C, Rose KL,et al. Hypohalous acids contribute to renal extracellular matrix damage in experimental diabetes[J].Diabetes, 2015,64(6):2242-2253.
[7] Zhang Y, Ruan YZ, Zhang P, et al. Increased indoleamine 2, 3-dioxygenase activity in type 2 diabetic nephropathy[J]. J Diabetes Complications, 2017,31(1):223-227.
[8] Brown J, Robusto B, Morel L. Intestinal dysbiosis and tryptophan metabolism in autoimmunity[J]. Front Immunol, 2020,11:1741.
[9] Hara K, Hirowatari Y, Shimura Y, et al. Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease[J]. Diabetes Res Clin Pract, 2011,94(2):167-171.
[10] Fukui M, Shiraishi E, Tanaka M, et al. Plasma serotonin is a predictor for deterioration of urinary albumin excretion in men with type 2 diabetes mellitus[J]. Metabolism, 2009,58(8):1076-1079.
[11] Saito J, Suzuki E, Tajima Y, et al. Increased plasma serotonin metabolite 5-hydroxyindole acetic acid concentrations are associated with impaired systolic and late diastolic forward flows during cardiac cycle and elevated resistive index at popliteal artery and renal insufficiency in type 2 diabetic patients with microalbuminuria[J]. Endocr J, 2016,63(1):69-76.
[12] De Mello VD, Paananen J, Lindström J, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study[J]. Sci Rep, 2017,7:46337.
[13] Tuomainen M, Lindström J, Lehtonen M, et al. Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals[J]. Nutr Diabetes, 2018,8(1):35.
[14] Tan YM, Gao Y, Teo G, et al. Plasma metabolome and lipidome associations with type 2 diabetes and diabetic nephropathy[J]. Metabolites, 2021,11(4):228.
